Drugs / SYH2072
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07647783 | Jan 2026 → Feb 2027 expected | — | InnovStone Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2025-12-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-13 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2025-12-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07647783 ↗ |
| Route | Oral | “SYH2072 tablets will be administered as a single or multiple oral doses.” NCT07647783 ↗ |